437 related articles for article (PubMed ID: 26739399)
1. Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
Groomes CL; Gianferante DM; Crouch GD; Parekh DS; Scott DW; Lieuw K
Pediatr Blood Cancer; 2016 May; 63(5):922-4. PubMed ID: 26739399
[TBL] [Abstract][Full Text] [Related]
2. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
[TBL] [Abstract][Full Text] [Related]
3. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
4. Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.
Ragni MV; Malec LM
Expert Rev Hematol; 2014 Dec; 7(6):747-55. PubMed ID: 25374055
[TBL] [Abstract][Full Text] [Related]
5. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
[TBL] [Abstract][Full Text] [Related]
6. What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?
Janbain M; Pipe S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):648-649. PubMed ID: 27913541
[TBL] [Abstract][Full Text] [Related]
7. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
[TBL] [Abstract][Full Text] [Related]
8. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.
Ay Y; Ersin T; Yesim O; Hilkay KT; Dilek I; Gulcihan O; Ahmet K
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):729-31. PubMed ID: 26484639
[TBL] [Abstract][Full Text] [Related]
9. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study.
Rivard GE; Rothschild C; Toll T; Achilles K
Haemophilia; 2013 May; 19(3):449-55. PubMed ID: 23510123
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
Thom K; Male C; Falger J; Pabinger I
Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
[TBL] [Abstract][Full Text] [Related]
11. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
Lin PC; Liao YM; Tsai SP; Chang TT
Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
[TBL] [Abstract][Full Text] [Related]
12. The importance of inhibitor eradication in clinically complicated hemophilia A patients.
Oldenburg J; Young G; Santagostino E; Escuriola Ettingshausen C
Expert Rev Hematol; 2018 Nov; 11(11):857-862. PubMed ID: 30286680
[TBL] [Abstract][Full Text] [Related]
13. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor.
Moorehead PC; Thibeault L; Tuttle A; Grabell J; Dwyre L; Silva M; James P; Lillicrap D
J Pediatr Hematol Oncol; 2015 May; 37(4):e220-2. PubMed ID: 25411864
[TBL] [Abstract][Full Text] [Related]
14. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors.
Unuvar A; Warrier I; Lusher JM
Haemophilia; 2000 May; 6(3):150-7. PubMed ID: 10792472
[TBL] [Abstract][Full Text] [Related]
15. Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.
Rivolta GF; Di Perna C; Franchini M; Riccardi F; Ippolito L; Lombardi M; Tagliaferri A
Blood Transfus; 2010 Jan; 8(1):66-8. PubMed ID: 20104281
[No Abstract] [Full Text] [Related]
16. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
[TBL] [Abstract][Full Text] [Related]
17. Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A.
Ebbert PT; Xavier F; Malec LM; Seaman CD; Ragni MV
Thromb Res; 2020 Nov; 195():51-54. PubMed ID: 32653601
[TBL] [Abstract][Full Text] [Related]
18. Escape or Fight: Inhibitors in Hemophilia A.
Merlin S; Follenzi A
Front Immunol; 2020; 11():476. PubMed ID: 32265927
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors: A Need for Eradication?
Santagostino E; Young G; Escuriola Ettingshausen C; Jimenez-Yuste V; Carcao M
Acta Haematol; 2019; 141(3):151-155. PubMed ID: 30783066
[TBL] [Abstract][Full Text] [Related]
20. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors.
Rocino A; Santagostino E; Mancuso ME; Mannucci PM
Haematologica; 2006 Apr; 91(4):558-61. PubMed ID: 16585022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
